About Sperm microtubule associated protein 2
Sperm microtubule associated protein 2 (SPMAP2) is a protein
from Homo sapiens identified by UniProt accession
Q9P2T0, 379 residues long.
MolForge cross-references it against 0 known binders and
109 disease associations.
Target properties
| Protein name | Sperm microtubule associated protein 2 |
| UniProt accession | Q9P2T0 |
| Gene | SPMAP2 |
| Organism | Homo sapiens |
| Length | 379 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (109)
Diseases linked to this target (Open Targets).
- azoospermia · score 0.10
- male infertility with teratozoospermia due to single gene mutation · score 0.09
- partial chromosome Y deletion · score 0.08
- spermatogenic failure, X-linked, 2 · score 0.08
- spermatogenic failure 65 · score 0.07
- familial male-limited precocious puberty · score 0.07
- spermatogenic failure 56 · score 0.07
- spermatogenic failure 72 · score 0.07
- spermatogenic failure, X-linked, 3 · score 0.07
- spermatogenic failure 46 · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9P2T0-F1 | alphafold | PREDICTED | 60.18 | — |
Amino-acid sequence (379 residues)
MGDSRRRSLG NQPSSEAAGR SEREQDGDPR GLQSSVYESR RVTDPERQDL DNAELGPEDP EEELPPEEVA GEEFPETLDP KEALSELERV LDKDLEEDIP EISRLSISQK LPSTTMTKAR KRRRRRRLME LAEPKINWQV LKDRKGRCGK GYAWISPCKM SLHFCLCWPS VYWTERFLED TTLTITVPAV SRRVEELSRP KRFYLEYYNN NRTTPVWPIP RSSLEYRASS RLKELAAPKI RDNFWSMPMS EVSQVSRAAQ MAVPSSRILQ LSKPKAPATL LEEWDPVPKP KPHVSDHNRL LHLARPKAQS DKCVPDRDPR WEVLDVTKKV VASPRIISLA KPKVRKGLNE GYDRRPLASM SLPPPKASPE KCDQPRPGL
Explore Sperm microtubule associated protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets